Skip to main content

Table 1 Clinical characteristics of patients with invasive candidiasis for crude 30-day mortality in the training and validation cohorts

From: A predictive nomogram for mortality of cancer patients with invasive candidiasis: a 10-year study in a cancer center of North China

Clinical characteristics Training cohort Validation cohort
No. patients (n = 147) 30-day mortality (n = 42) p value a No. patients (n = 60) 30-day mortality (n = 16) p value a
Male (%) 75 (51.0) 20 (47.6) 0.715 36 (60.0) 9 (56.3) 0.771
Age > = 65 years old (%) 68 (46.3) 21 (50.0) 0.587 22 (36.7) 6 (37.5) 1.000
LOS > = 30 days (%) 50 (34.0) 18 (42.9) 0.179 19 (31.7) 5 (31.3) 1.000
CVC > 7 days (%) 79 (53.7) 24 (57.1) 0.715 35 (58.3) 12 (75.0) 0.146
TPN > 5 days (%) 54 (36.7) 16 (38.1) 0.851 21 (35.0) 7 (43.8) 0.541
Urinary catheter > 2 days (%) 41 (27.9) 13 (31.0) 0.685 21 (35.0) 8 (50.0) 0.220
Nasogastric tube > 3 days (%) 60 (40.8) 14 (33.3) 0.270 24 (40.0) 7 (43.8) 0.771
No prior surgery (%) 68 (46.3) 30 (71.4) <  0.001 41 (68.3) 14 (87.5) 0.066
Neutropenia (%) 9 (6.1) 3 (7.1) 0.715 3 (5.0) 2 (12.5) 0.171
Chemotherapy (%) 50 (34.0) 15 (35.7) 0.848 11 (18.3) 4 (25.0) 0.462
Metastasis (%) 50 (34.0) 28 (66.7) <  0.001 24 (40.0) 9 (56.3) 0.145
ICU admitted > 3 days (%) 54 (36.7) 26 (61.9) <  0.001 26 (43.3) 11 (68.8) 0.021
Previous antibiotics exposure (%) 104 (70.7) 31 (73.8) 0.691 41 (68.3) 10 (62.5) 0.550
Timely anti-fungal treatment 101 (68.7) 31 (73.8) 0.437 42 (70.0) 14 (87.5) 0.112
Fluconazole prophylaxis 11 (7.5) 5 (11.9) 0.295 9 (15.0) 5 (31.3) 0.048
No source control 59 (40.1) 32 (76.2) <  0.001 29 (48.3) 11 (68.8) 0.081
Site of infection
 Bloodstream 51 (34.7) 25 (59.5) < 0.001 22 (36.7) 11 (68.8) 0.005
 Abdominal cavity 67 (45.6) 12 (28.6) 0.010 33 (55.0) 4 (25.0) 0.008
 Thoracic cavity 17 (11.6) 3 (7.1) 0.397 2 (3.3) 0 1.000
 Pelvic cavity 12 (8.2) 2 (4.8) 0.510 3 (5.0) 1 (6.3) 1.000
Candida species
Candida albicans 72 (49.0) 18 (42.9) 0.367 28 (46.7) 4 (25.0) 0.077
Candida glabrata complex 40 (27.2) 16 (38.1) 0.068 10 (16.7) 6 (37.5) 0.017
Candida tropicalis 11 (7.5) 3 (7.1) 1.000 10 (16.7) 3 (18.8) 1.000
Candida parapsilosis complex 9 (6.1) 3 (7.1) 0.715 6 (10.0) 2 (12.5) 0.653
 Other Candida species b 15 (10.2) 2 (4.8) 0.233 6 (10.0) 1 (6.3) 1.000
Tumor types
 Gastrointestinal 50 (34.0) 13 (31.0) 0.702 23 (38.3) 7 (43.8) 0.765
 Hepatic-pancreatic 57 (38.8) 19 (45.2) 0.351 22 (36.7) 4 (25.0) 0.367
 Hematologic malignancy 9 (6.1) 4 (9.5) 0.276 4 (6.7) 2 (12.5) 0.287
 Others c 31 (21.1) 6 (14.3) 0.265 11 (18.3) 3 (18.8) 1.000
Co-morbidities
 Diabetes mellitus 28 (19.0) 9 (21.4) 0.647 14 (23.3) 4 (25.0) 1.000
 Live dysfunction 30 (20.4) 9 (21.4) 0.825 14 (23.3) 4 (25.0) 1.000
 Kidney dysfunction 23 (15.6) 8 (19.0) 0.462 4 (6.7) 3 (18.8) 0.054
 Respiratory dysfunction 22 (15.0) 4 (9.5) 0.311 6 (10.0) 3 (18.8) 0.328
 Cardiovascular dysfunction 20 (13.6) 8 (19.0) 0.286 1 (1.7) 1 (6.3) 0.267
  1. LOS length of hospital stay, CVC central venous catheters, TPN total parenteral nutrition, ICU intensive care unit
  2. a Fisher exact test were compared between patient alive vs deceased in 30-day
  3. b In the training cohort: Candida lusitaniae (n = 7), Candida ciferrii (n = 3), Candida famata (n = 4) and Candida krusei (n = 1); In the validation cohort: Candida lusitaniae (n = 2), Candida ciferrii (n = 2), Candida famata (n = 1) and Candida krusei (n = 1)
  4. c In the training cohort: lung cancer (n = 11), ovarian cancer (n = 7), renal cancer (n = 3), thymoma (n = 3), breast cancer (n = 2), giiomas (n = 1), rhabdomyosarcoma (n = 1), endometrial cancer (n = 1), liposarcoma (n = 1), nephroblastoma (n = 1); In the validation cohort: lung cancer (n = 2), ovarian cancer (n = 2), renal cancer (n = 2), cervical cancer (n = 2), nephroblastoma (n = 1), liposarcoma (n = 1), fibrosarcoma (n = 1)
\